XTX Topco Ltd Takes $246,000 Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

XTX Topco Ltd purchased a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the third quarter, Holdings Channel reports. The institutional investor purchased 112,713 shares of the company’s stock, valued at approximately $246,000.

Several other hedge funds and other institutional investors have also bought and sold shares of VTYX. State Street Corp boosted its holdings in shares of Ventyx Biosciences by 0.8% in the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after buying an additional 9,783 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Ventyx Biosciences by 19.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 568,479 shares of the company’s stock worth $1,239,000 after acquiring an additional 92,753 shares during the last quarter. Vestal Point Capital LP raised its stake in Ventyx Biosciences by 31.2% in the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after acquiring an additional 410,000 shares during the period. Sio Capital Management LLC lifted its holdings in Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Ventyx Biosciences by 3.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company’s stock worth $1,058,000 after purchasing an additional 17,898 shares during the period. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Insider Buying and Selling at Ventyx Biosciences

In other Ventyx Biosciences news, CEO Raju Mohan purchased 238,248 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was purchased at an average price of $1.83 per share, for a total transaction of $435,993.84. Following the transaction, the chief executive officer now owns 1,913,276 shares in the company, valued at $3,501,295.08. The trade was a 14.22 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 18.18% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. Oppenheimer reissued an “outperform” rating and set a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Ventyx Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Trading Down 3.0 %

VTYX stock opened at $2.30 on Thursday. The firm has a 50 day moving average of $2.30 and a 200-day moving average of $2.40. The firm has a market capitalization of $162.64 million, a P/E ratio of -0.97 and a beta of 0.48. Ventyx Biosciences, Inc. has a 12 month low of $1.67 and a 12 month high of $11.48.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.